Iteos Therapeutics Stock Forward View

Iteos Therapeutics Additional Predictive Modules

Most predictive techniques to examine Iteos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Iteos using various technical indicators. When you analyze Iteos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur. A naive forecasting model for Iteos Therapeutics is a special case of the moving average forecasting where the number of periods used for smoothing is one. Therefore, the forecast of Iteos Therapeutics value for a given trading day is simply the observed value for the previous period. Due to the simplistic nature of the naive forecasting model, it can only be used to forecast up to one period.

Iteos Therapeutics Naive Prediction Price Forecast For the 8th of February

Given 90 days horizon, the Naive Prediction forecasted value of Iteos Therapeutics on the next trading day is expected to be 10.13 with a mean absolute deviation of 0.04, mean absolute percentage error of 0, and the sum of the absolute errors of 2.71.

Iteos Therapeutics Stock Forecast Pattern

Backtest Iteos Therapeutics

Iteos Therapeutics Price Prediction

Research Analysis

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Iteos Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Iteos Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality. This model is not at all useful as a medium-long range forecasting tool of Iteos Therapeutics. This model is simplistic and is included partly for completeness and partly because of its simplicity. It is unlikely that you'll want to use this model directly to predict Iteos Therapeutics. Instead, consider using either the moving average model or the more general weighted moving average model with a higher (i.e., greater than 1) number of periods, and possibly a different set of weights.

Predictive Modules for Iteos Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Iteos Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Hype Prediction Low Estimated High 10.15 10.15 10.15 Details

Intrinsic Valuation Low Real High 8.63 8.63 11.17 Details

Bollinger Band Projection (param) Low Middle High 9.98 10.14 10.30 Details

Iteos Therapeutics After-Hype Price Density Analysis

Iteos Therapeutics Estimiated After-Hype Price Volatility

Iteos Therapeutics Stock Price Outlook Analysis

Notes

Iteos Therapeutics Hype Timeline

Iteos Therapeutics is currently traded for 10.15. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Iteos is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Iteos Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 10.15. About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 4.73. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in about 7 days. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Iteos Therapeutics Related Hype Analysis

Iteos Therapeutics Related Equities

Risk & Return

Correlation

Iteos Therapeutics Market Strength Events

Iteos Therapeutics Risk Indicators

Story Coverage note for Iteos Therapeutics

Iteos Therapeutics Short Properties

Other Consideration for investing in Iteos Stock